This company listing is no longer active
0C8 Stock Overview
Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Catalent, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.93 |
| 52 Week High | US$60.22 |
| 52 Week Low | US$38.05 |
| Beta | 1.14 |
| 1 Month Change | 8.37% |
| 3 Month Change | 10.84% |
| 1 Year Change | 57.50% |
| 3 Year Change | -43.46% |
| 5 Year Change | 19.86% |
| Change since IPO | 293.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0C8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -0.5% | -0.5% |
| 1Y | 57.5% | -13.0% | 15.5% |
Return vs Industry: 0C8 exceeded the German Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: 0C8 exceeded the German Market which returned 9.2% over the past year.
Price Volatility
| 0C8 volatility | |
|---|---|
| 0C8 Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 0C8 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0C8's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 16,900 | Alessandro Maselli | www.catalent.com |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Catalent, Inc. Fundamentals Summary
| 0C8 fundamental statistics | |
|---|---|
| Market cap | €10.99b |
| Earnings (TTM) | -€393.80m |
| Revenue (TTM) | €4.22b |
2.6x
P/S Ratio-27.9x
P/E RatioIs 0C8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0C8 income statement (TTM) | |
|---|---|
| Revenue | US$4.42b |
| Cost of Revenue | US$3.46b |
| Gross Profit | US$965.00m |
| Other Expenses | US$1.38b |
| Earnings | -US$413.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.28 |
| Gross Margin | 21.82% |
| Net Profit Margin | -9.34% |
| Debt/Equity Ratio | 130.0% |
How did 0C8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 14:14 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Catalent, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Parth Talsania | Equisights |
| Gary Nachman | Goldman Sachs |
| Rachel Vatnsdal Olson | J.P. Morgan |